CD19/CD22 Dual‐Targeted CAR‐T Therapy Active in Relapsed/Refractory DLBCL

Những quyển sách tương tự

• Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
  Bằng: Tabbara, Nadeem, et al.
  Được phát hành: (2021)
• Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
  Bằng: Dai, Hanren, et al.
  Được phát hành: (2020)
• Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
  Bằng: Dai, Hanren, et al.
  Được phát hành: (2020)
• First Allogeneic CAR T‐Cell Therapy Impresses in Relapsed/Refractory Lymphoma
  Được phát hành: (2020)
• Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
  Bằng: Zhu, Haibo, et al.
  Được phát hành: (2021)